This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Evidence-Based Medicine  • Randomized Controlled Trial  • Hypertension  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: In the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT),¹ there were more deaths, cardiovascular events, and strokes in patients whose hypertension was treated with a -blocker (supplemented with a diuretic) than those treated with a calcium channel blocker (supplemented with an angiotensin-converting enzyme inhibitor). In their Commentary, Dr Psaty and colleagues² discuss ASCOT and assert that it was fatally flawed because diuretics (which they describe as "unsurpassed" in the treatment of hypertension) were not given to 45% of the individuals in the -blocker arm. They also consider that atenolol, the -blocker used in ASCOT, is less cardioprotective than other -blockers.

However, the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), the largest direct comparison of diuretics, calcium channel blockers, and angiotensin-converting enzyme inhibitors, did not demonstrate that diuretics were superior to other antihypertensive medications. Rather, it found that they had similar efficacy as treatment with other single . . . [Full Text of this Article]

Simeon Pollack, MD
simeonpollack@optonline.net
Department of Medicine
Albert Einstein College of Medicine
Bronx, NY

RELATED ARTICLES

Clinical Trials in Hypertension
Franz H. Messerli, Gareth Beevers, Stanley S. Franklin, and Thomas G. Pickering
JAMA. 2006;296(12):1463.
EXTRACT | FULL TEXT  

Clinical Trials in Hypertension—Reply
Bruce M. Psaty, Noel S. Weiss, and Curt D. Furberg
JAMA. 2006;296(12):1464-1465.
EXTRACT | FULL TEXT  

Recent Trials in Hypertension: Compelling Science or Commercial Speech?
Bruce M. Psaty, Noel S. Weiss, and Curt D. Furberg
JAMA. 2006;295(14):1704-1706.
EXTRACT | FULL TEXT